Impact of pelvic dynamic acquisition on final reading of
18F-FCH
PET
acquisition protocol
dynamic
prostate cancer
treatment
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
02
03
2021
accepted:
11
07
2021
pubmed:
30
7
2021
medline:
6
4
2022
entrez:
29
7
2021
Statut:
ppublish
Résumé
Despite the increasing use of All 221 consecutive PET/CT were selected from 201 patients previously treated by radical prostatectomy (n = 31), pelvic radiation therapy (n = 60), or both (n = 94). 24 patients had no previous treatments, and 12 benefited from other focal treatments. In the whole population, dynamic acquisition modified final interpretation of 32/221 scans (14.5%) for residents, 26 (11.8%) for experts and 19 (8.6%) for consensual reading. No influence of previous treatments was found. The availability of a dynamic phase would have been responsible for treatment modification in 5/221 scans (2.3%). Considering only the prostate bed, dynamic acquisition modified the final interpretation in 7/125 (5.6%) studies (consensual reading) from patients with previous prostatic surgery and 4/84 (4.8%) scans from patients without a history of prostatic surgical intervention. No significant influence of dynamic acquisition was found on the final PET interpretation on prostate lodge accordingly to previous prostatic surgery. The dynamic phase changes the interpretation of
Identifiants
pubmed: 34323005
doi: 10.1111/1754-9485.13296
doi:
Substances chimiques
fluorocholine
6029HGL0QP
Choline
N91BDP6H0X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
324-331Informations de copyright
© 2021 The Royal Australian and New Zealand College of Radiologists.
Références
Ferlay J, Colombet M, Soerjomataram I et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-87.
Giovacchini G, Giovannini E, Leoncini R, Riondato M, Ciarmiello A. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. Eur J Nucl Med Mol Imaging 2017; 44: 1751-76.
Cornford P, van den Bergh RCN, Briers E et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 2021; 79: 263-82.
Lowrance WT, Breau RH, Chou R et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J Urol 2021; 205: 14-21.
Chondrogiannis S, Marzola MC, Grassetto G et al. Optimized protocol for 18F-Choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases. Clin Nucl Med 2015; 40: e308-12.
DeGrado TR, Kwee SA, Coel MN, Coleman RE. The impact of urinary excretion of (18)F-labeled choline analogs. J Nucl Med 2007; 48: 1225.
Garcia JR, Cozar M, Soler M et al. Standardization of acquisition protocols using PET/CT with 18F-Choline in prostate cancer. Rev Esp Med Nucl Imagen Mol 2020; 39: 204-11.
Rubello D, Massaro A, Ferretti A et al. Optimising 18 F-choline PET/CT acquisition protocol in prostate cancer patients. N Am J Med Sci 2012; 4: 416.
Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-Fluorocholine PET. J Nucl Med 2006; 47: 262-9.
Di Biagio D, Chiaravalloti A, Tavolozza M, Abbatiello P, Schillaci O. Detection of local recurrence of prostate cancer after radical prostatectomy: is there a role for early 18F-FCH PET/CT? Ann Nucl Med 2015; 29: 861-9.
von Eyben FE, Kairemo K. Acquisition with 11C-choline and 18F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Ann Nucl Med 2016; 30: 385-92.
Frood R, Baren J, McDermott G, Bottomley D, Patel C, Scarsbrook A. Diagnostic performance of a streamlined 18 F-choline PET-CT protocol for the detection of prostate carcinoma recurrence in combination with appropriate-use criteria. Clin Radiol 2018; 73: 632-9.
Phillips R, Shi WY, Deek M et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the oriole phase 2 randomized clinical trial. JAMA Oncol 2020; 6: 650.
Ost P, Reynders D, Decaestecker K et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018; 36: 446-53.
Simone G, Di Pierro GB, Papalia R et al. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with 18F-fluorocholine positron emission tomography/computed tomography. World J Urol 2015; 33: 1511-8.
Evangelista L, Cervino AR, Guttilla A, Zattoni F, Cuccurullo V, Mansi L. 18F-fluoromethylcholine or 18F-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision. Nucl Med Biol 2015; 42: 340-8.
Colombié M, Campion L, Bailly C et al. Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 1784-93.
Cimitan M, Evangelista L, Hodoli M et al. Gleason score at diagnosis predicts the rate of detection of 18F-Choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients. J Nucl Med 2015; 56: 209-15.
Giovacchini G, Giovannini E, Borsò E et al. Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer. Nucl Med Commun 2019; 40: 258-63.
Kjölhede H, Almquist H, Lyttkens K, Bratt O. Pre-treatment 18F-choline PET/CT is prognostic for biochemical recurrence, development of bone metastasis, and cancer specific mortality following radical local therapy of high-risk prostate cancer. Eur J Hybrid Imaging 2018; 2: 16.
Siminiak N, Wojciechowska K, Miechowicz I, Cholewiński W, Ruchała M, Czepczyński R. 18F-choline positron emission tomography/computed tomography for the detection of prostate cancer relapse: assessment of maximum standardized uptake value correlation with prostate-specific antigen levels. Nucl Med Commun 2019; 40: 1263-7.
Niziers V, Boissier R, Borchiellini D et al. “Real-world” evaluation of 18F-Choline PET/CT practices in prostate cancer patients and impact on changes in therapeutic strategy. Urol Oncol Semin Orig Investig 2020; 38: 2.e1-9.